Arbutus Biopharma
ABUS
24 hedge funds and large institutions have $39.5M invested in Arbutus Biopharma in 2013 Q4 according to their latest regulatory filings, with 12 funds opening new positions, 6 increasing their positions, 1 reducing their positions, and 6 closing their positions.
500% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 1
341% more capital invested
Capital invested by funds: $8.95M → $39.5M (+$30.5M)
100% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 6
33% more funds holding
Funds holding: 18 → 24 (+6)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Franklin Resources
San Mateo,
California
|
+$16.8M |
| 2 |
SM
Sabby Management
Miami Beach,
Florida
|
+$4.32M |
| 3 |
BBA
Baker Bros. Advisors
New York
|
+$4.16M |
| 4 |
PC
PointState Capital
New York
|
+$2.9M |
| 5 |
AWMDMG
Austin W. Marxe & David M. Greenhouse
New York
|
+$1.76M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
-$1.11M |
| 2 |
KA
Kerrisdale Advisers
Miami,
Florida
|
-$626K |
| 3 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$410K |
| 4 |
LOM
Loeb Offshore Management
New York
|
-$70K |
| 5 |
FANJ
Financial Architects (New Jersey)
Marlton,
New Jersey
|
-$63K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
KA
26
Kerrisdale Advisers
Miami,
Florida
| – | -$626K | -90,057 | Closed |
|
|
LOM
27
Loeb Offshore Management
New York
| – | -$70K | -10,000 | Closed |
|
|
FANJ
28
Financial Architects (New Jersey)
Marlton,
New Jersey
| – | -$63K | -9,000 | Closed |
|
29
Barclays
London,
United Kingdom
| – | -$2K | -400 | Closed |
|
30
Wells Fargo
San Francisco,
California
| – | -$1K | -200 | Closed |
|
ABUS Hedge Fund Activity: Q4 2013 in Review
24 of the 3,445 institutional investors tracked by Wall St. Rank reported a position in Arbutus Biopharma (ABUS) for Q4 2013, worth a combined $39.5M — up 341% from $8.95M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new ABUS positions and 6 closed out — a net gain of 6 holders — while 6 added to existing stakes and 1 trimmed.
The largest buyer was Franklin Resources, opening a new position worth an estimated $16.8M. The largest seller was Perceptive Advisors, exiting entirely with an estimated $1.11M sold.
- 24 institutional investors held Arbutus Biopharma (ABUS) as of Q4 2013, up from 18 in Q3 2013.
- Funds reported $39.5M of Arbutus Biopharma stock for Q4 2013, up 341% quarter-over-quarter.
- 12 funds opened new Arbutus Biopharma positions in Q4 2013 and 6 closed out, a net change of +6 holders.
- The largest Arbutus Biopharma buyer in Q4 2013 was Franklin Resources, an estimated $16.8M added.
- The largest Arbutus Biopharma seller in Q4 2013 was Perceptive Advisors, an estimated $1.11M sold.
Based on aggregated 13F filings for Q4 2013.